West to Host First-Quarter 2025 Conference Call
Werte in diesem Artikel
EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.
The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.
A slide presentation will be made available on the day of the call in the Investors section of the Company's website. A replay of the conference call and webcast will be available on the Company's website. Replay of the webcasts will be available for approximately 90 days after the event.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
View original content to download multimedia:https://www.prnewswire.com/news-releases/west-to-host-first-quarter-2025-conference-call-302424869.html
SOURCE West Pharmaceutical Services, Inc.
Übrigens: West Pharmaceutical Services und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf West Pharmaceutical Services
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf West Pharmaceutical Services
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu West Pharmaceutical Services Inc.
Analysen zu West Pharmaceutical Services Inc.
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2012 | West Pharmaceutical Services hold | Jefferies & Company Inc. | |
14.05.2010 | West Pharmaceutical Services neutral | UBS AG | |
06.11.2007 | West Pharmaceutical Services buy | UBS AG | |
08.10.2007 | West Pharmaceutical Services neues Kursziel | UBS AG | |
20.08.2007 | West Pharmaceutical Services Ersteinschätzung | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2007 | West Pharmaceutical Services buy | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2012 | West Pharmaceutical Services hold | Jefferies & Company Inc. | |
14.05.2010 | West Pharmaceutical Services neutral | UBS AG | |
08.10.2007 | West Pharmaceutical Services neues Kursziel | UBS AG | |
20.08.2007 | West Pharmaceutical Services Ersteinschätzung | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für West Pharmaceutical Services Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen